DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

Information source: Procter and Gamble
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteogenesis Imperfecta

Intervention: risedronate sodium (Actonel) (Drug); Placebo (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: Procter and Gamble

Official(s) and/or principal investigator(s):
Dietrich H Wenderoth, MD, Study Director, Affiliation: Procter and Gamble

Summary

Children with Osteogenesis Imperfecta (OI) have bone pain, low bone mass and fractures. There are no approved drugs for the treatment of OI in children, even though some intravenous (IV) bisphosphonates are used off-label in some countries. In a single dose, pharmacokinetic study, data showed that risedronate was well tolerated in 28 children with OI. This three year study will test the safety and efficacy of risedronate in the treatment of children with OI. For the first year, patients will be randomized to the risedronate and placebo groups in a 2: 1 ratio (two groups will receive risedronate, and one group will receive placebo). For the second and third years of the study, all patients will receive risedronate.

Clinical Details

Official title: Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: The primary objective of the study is to determine the efficacy of risedronate compared to placebo in children 4 to <16 years of age with osteogenesis imperfecta as assessed by percent change from Baseline in lumbar spine bone mineral density at Month 12

Eligibility

Minimum age: 4 Years. Maximum age: 15 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- OI diagnosis

- increased risk of fracture: either has a history of at least 1 radiographically

confirmed, non-traumatic or low impact fracture plus low bone mineral density (BMD) or has very low BMD with or without a history of fractures.

Exclusion Criteria:

- Any bisphosphonate use within one year of enrollment

Locations and Contacts

Royal Hospital for Sick Children, Glasgow G3 8SJ, United Kingdom

Sheffield Children's Hospital, Sheffield S210 2TH, United Kingdom

University of Nebraska Medical Center, Children's Hospital, Omaha, Nebraska 68114, United States

Hospital for Special Surgery, New York, New York 10021, United States

Wright State University BioMedical Imaging Laboratory and Miami Valley Hospital, Dayton, Ohio 45409, United States

Oregon Health & Science University, Portland, Oregon 97239, United States

Additional Information

Starting date: August 2004
Ending date: March 2010
Last updated: February 13, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014